Drugs for the control of parasitic diseases: Current status and development in schistosomiasis

Trends in Parasitology

Volumn 19, Issue 11, 2003, Pages 509-515

  Fenwick, Alan ^a   Savioli, Lorenzo ^b   Engels, Dirk ^b   Bergquist, N Robert ^c   Todd, Matthew H ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c University of London ^*  (Sweden)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMISININ DERIVATIVE; METRIFONATE; NIRIDAZOLE; OXAMNIQUINE; PRAZIQUANTEL;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COST OF ILLNESS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EGYPT; EPIDEMIOLOGICAL DATA; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; MALARIA; MORBIDITY; PARASITOSIS; PREVALENCE; REVIEW; SCHISTOSOMIASIS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

COMMIPHORA; PROTOZOA;

EID: 0142227135     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.09.005     Document Type: Review

References (51)

1. Chitsulo L., et al. The global status of schistosomiasis and its control. Acta Trop. 77:2000;41-51.
2. Van der Werf M.J., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 86:2003;125-139.
3. WHO (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis. Report of a WHO Expert Committee. WHO Tech. Rep. Ser. 912, WHO, Geneva.
4. Guyatt H.L., et al. Evaluation of efficacy of school-based anthelmintic treatments against anaemia in children in the United Republic of Tanzania. Bull. WHO. 79:2001;695-703.
5. Better health, nutrition and education for the school aged child. Trans. R. Soc. Trop. Med. Hyg. 91:1997;1-2.
6. Engels D., et al. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop. 82:2002;139-146.
7. Katz N. Schistosomiasis in Brazil. Mem. Inst. Oswaldo Cruz. 93:(Suppl. 1):1998;33-35.
8. Leonardo L.R., et al. Difficulties and strategies in the control of schistosomiasis in the Philippines. Acta Trop. 82:2002;295-299.
9. Yuan H.C., et al. The 1992-1999 World Bank schistosomiasis research initiative in China: outcome and perspectives. Parasitol. Int. 49:2000;195-207.
10. Zhang W., Wong C.M. Evaluation of the 1992-1999 World Bank schistosomiasis control project in China. Acta Trop. 85:2003;303-313.
11. Savioli L., et al. Schistosomiasis and soil-transmitted helminth infections: forging control efforts. Trans. R. Soc. Trop. Med. Hyg. 96:2002;577-579.
12. van der Werf, et al. Schistosomiasis control in Ghana: case management and means for diagnosis and treatment within the health system. Trans. R. Soc. Trop. Med. Hyg. 86:2003;125-139.
13. Miguel, E. and Kremer, M. Worms: education and health externalities in Kenya. Econometrica (in press).
14. Lengeler C., et al. Questionnaires for rapid screening of schistosomiasis in sub-Saharan Africa. Bull. WHO. 80:2002;235-242.
15. Hall A., et al. Alternatives to body weight for estimating the dose of praziquantel needed to treat schistosomiasis. Trans. R. Soc. Trop. Med. Hyg. 93:1999;653-658.
16. Montresor A., et al. Development and validation of a 'tablet pole' for the administration of praziquantel in sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg. 95:2001;542-544.
17. Montresor A., et al. Field test of the 'dose pole' for praziquantel in Zanzibar. Trans. R. Soc. Trop. Med. Hyg. 96:2002;323-324.
18. Olds G.R. Administration of praziquantel to pregnant and lactating women. Acta Trop. 86:2003;185-195.
19. Bundy D.A., De Silva N.R. Can we deworm this wormy world? Br. Med. Bull. 54:1998;421-432.
20. Montresor A., et al. Extending anthelminthic coverage to non-enrolled school-age children using a simple and low-cost method. Trop. Med. Int. Health. 6:2001;535-537.
21. Kusel J., Hagan P. Praziquantel - its use, cost and possible development of resistance. Parasitol. Today. 15:1999;352-354.
22. Doenhoff M., et al. Praziquantel and the control of schistosomiasis. Parasitol. Today. 16:2000;364-366.
23. Appleton C.C., Mbaye A. Praziquantel - quality, dosages and markers of resistance. Trends Parasitol. 17:2001;356-357.
24. Sulaiman S.M., et al. Counterfeit praziquantel. Lancet. 358:2001;666-667.
25. El-Subbagh H.I., Al-Badr A.A. Praziquantel. Anal. Prof. Drug Subst. Excip. 25:1998;463-500.
26. PZQ patents a) Seubert, J., Thomas, H., Andrews, P. German Patent Application 2,362,539. b) Seubert, J. German Patent Application 2,504,250. c) Pohlke, R., Loebich, F., Seubert, J., Thomas, H., Andrews, P. German Patent Application 2,331,713.
27. PZQ patents a) Seubert, J., Thomas, H., Andrews, P. German Patent Application 2,362,539. b) Seubert, J. German Patent Application 2,504,250. c) Pohlke, R., Loebich, F., Seubert, J., Thomas, H., Andrews, P. German Patent Application 2,331,713.
28. PZQ patents a) Seubert, J., Thomas, H., Andrews, P. German Patent Application 2,362,539. b) Seubert, J. German Patent Application 2,504,250. c) Pohlke, R., Loebich, F., Seubert, J., Thomas, H., Andrews, P. German Patent Application 2,331,713.
29. Seubert, J. German Patent Application 2,418,111.
30. Blehaut J., et al. Industrial chiral chromatography: the keys to rapid process development and successful implementation (Part 1). Chimica Oggi-Chemistry Today. 19:2001;24-28.
31. Doenhoff M., et al. Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans. R. Soc. Trop. Med. Hyg. 96:2002;465-469.
32. Danso-Appiah A., De-Vlas S.J. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. 18:2002;125-129.
33. Geerts S., Gryseels B. Anthelmintic resistance in human helminths: a review. Trop. Med. Int. Health. 6:2001;915-921.
34. Ismail M., et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. 60:1999;932-935.
35. Seubert J., et al. Synthesis and properties of PZQ, a novel broad spectrum antihelmintic with excellent activity against Schistosomes and Cestodes. Experientia. 33:1977;1036-1037.
36. Todd M.H., et al. Amino acid-derived heterocycles: Lewis acid-catalyzed and radical cyclizations from peptide acetals. J. Org. Chem. 67:2002;3985-3988.
37. Andrews P., et al. Praziquantel. Med. Res. Rev. 3:1983;147-200.
38. Valls N., et al. Praziquantel analogues (II) Synthesis of 4-oxo-octahydro-pyrazino[1′,2′:1,2]pyrido[3,4-b]- and -[4,3-b] indoles. Heterocycles. 29:1989;231-234.
39. Abo-Ghalia M.H., Soliman A.E.M. Synthesis and antischistosomal activity of a new 2-nicotinoyl dipeptide analogue of praziquantel. Arzneimittelforschung. 46:1996;207-209.
40. Kim C., Min D.Y. Synthesis of praziquantel derivatives and their in vitro activity against adult Clonorchis sinensis. Arch. Pharm. Res. 21:1998;744-748.
41. Le W.J., et al. Studies on the efficacy of artemether in experimental schistosomiasis. Yao Xue Xue Bao. 17:1982;187-193.
42. Le W.J., et al. Chemotherapeutic effect of artesunate in experimental schistosomiasis. Yao Xue Xue Bao. 18:1983;619-621.
43. Utzinger J., et al. The potential of artemether for the control of schistosomiasis (Review). Int. J. Parasitol. 31:2001;1549-1562.
44. Xiao S.H., Catto B.A. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob. Agents Chemother. 33:1989;1557-1562.
45. Utzinger J., et al. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 355:2000;1320-1325.
46. N'Goran E.K., et al. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am. J. Trop. Med. Hyg. 68:2003;24-32.
47. Utzinger J., et al. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob. Agents Chemother. 47:2003;1487-1495.
48. Sheir Z., et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am. J. Trop. Med. Hyg. 65:2001;700-704.
49. Van der Werf M.J., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta. Trop. 86:2003;125-139.
50. Kheir M.M. Mortality due to schistosomiasis mansoni: a field study in Sudan. Am. J. Trop. Med. Hyg. 60:1999;307-310.
51. Blas B.L., et al. An attempt to study the case fatality rate in Schistosoma japonicum infection in the Philippines. Southeast Asian J. Trop. Med. Public. Health. 17:1986;67-70.